Author

E. H. J. Danen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

A. Botto· 1 shared A. Gregori· 1 shared A. J. M. Zweemer· 1 shared A. Trapman-Jansen· 1 shared B. van de Water· 1 shared C. Bergonzini· 1 shared C.-Y. Liao· 1 shared D. Hammerl· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Botto

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models

D. Kortleve, D. Hammerl, M. van Brakel, R. Wijers, D. Roelofs, K. Kroese, M. Timmermans, C.-Y. Liao, A. Trapman-Jansen, R. Foekens, J. Michaux, M. de Beijer, S. I. Buschow, J. A. Demmers, M. Kok, , R. Debets

This study identifies ROPN1 as a target for TCR-engineered T-cells effective against TNBC in preclinical models and demonstrates their safety and efficacy.

bioRxiv · Jan 10, 2024 · PreprintImmunology

ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells

C. Bergonzini, A. Gregori, T. M. S. Hagens, V. E. van der Noord, B. van de Water, A. J. M. Zweemer, M. Capula, G. Mantini, A. Botto, F. Finamore, I. Garajova, L. A. McDonnell, T. Schmidt, E. Giovannetti, E. H. J. Danen

This study identifies ABCB1 overexpression via locus amplification as a conserved mechanism of paclitaxel resistance in PDAC and shows that targeting ABCB1 can sensitize resistant cells to treatment.

bioRxiv · May 30, 2023 · PreprintCancer Biology